Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma

Raymond K. Mulhern, Shawna L. Palmer, Thomas E. Merchant, Dana Wallace, Mehmet Kocak, Pim Brouwers, Kevin Krull, Murali Chintagumpala, Robyn Stargatt, David M. Ashley, Vida L. Tyc, Larry Kun, James Boyett, Amar Gajjar

Research output: Contribution to journalArticle

249 Citations (Scopus)

Abstract

Purpose: This prospective, longitudinal study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions of dose with age and time from diagnosis on intelligence quotient (IQ) and academic achievement (reading, spelling, and math) among patients treated for medulloblastoma (MB). Patients and Methods: Patients received serial neurocognitive testing spanning from 0 to 6.03 years after diagnosis (median, 3.14 years). The multi-institutional study included 111 patients, who were 3 to 20 years of age at diagnosis (median age, 7.4 years), treated for MB with risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and vincristine) with stem-cell support. High-risk patients (HR; n = 37) received CSI to 36 to 39.6 Gy and conformal boost treatment of the primary site to 55.8 to 59.4 Gy. Average-risk patients (AR; n = 74) received CSI to 23.4 Gy and conformal boost treatment of the posterior fossa to 36.0 Gy and primary site to 55.8 Gy. Results: Multivariate modeling revealed statistically significant declines in mean IQ (-1.59 points/yr; P= .006), reading (-2.95 points/yr; P < .0001), spelling (-2.94 points/yr; P < .0001), and math (-1.87 points/yr; P = .003) scores for the entire group. The effects of risk-adapted radiation therapy on IQ, reading, and spelling were moderated by age, with the greatest rates of decline observed for the HR patients who were younger (< 7 years old) at diagnosis. Conclusion: Young age at diagnosis was the most prominent risk factor for neurocognitive deficits among survivors of MB despite reductions in CSI dosing and efforts to limit the boost volume. Younger patients exhibited substantial problems with the development of reading skills.

Original languageEnglish (US)
Pages (from-to)5511-5519
Number of pages9
JournalJournal of Clinical Oncology
Volume23
Issue number24
DOIs
StatePublished - Dec 1 2005

Fingerprint

Medulloblastoma
Craniospinal Irradiation
Reading
Intelligence
Therapeutics
Vincristine
Cyclophosphamide
Cisplatin
Longitudinal Studies
Survivors
Radiotherapy
Stem Cells
Prospective Studies
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Mulhern, R. K., Palmer, S. L., Merchant, T. E., Wallace, D., Kocak, M., Brouwers, P., ... Gajjar, A. (2005). Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. Journal of Clinical Oncology, 23(24), 5511-5519. https://doi.org/10.1200/JCO.2005.00.703

Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. / Mulhern, Raymond K.; Palmer, Shawna L.; Merchant, Thomas E.; Wallace, Dana; Kocak, Mehmet; Brouwers, Pim; Krull, Kevin; Chintagumpala, Murali; Stargatt, Robyn; Ashley, David M.; Tyc, Vida L.; Kun, Larry; Boyett, James; Gajjar, Amar.

In: Journal of Clinical Oncology, Vol. 23, No. 24, 01.12.2005, p. 5511-5519.

Research output: Contribution to journalArticle

Mulhern, RK, Palmer, SL, Merchant, TE, Wallace, D, Kocak, M, Brouwers, P, Krull, K, Chintagumpala, M, Stargatt, R, Ashley, DM, Tyc, VL, Kun, L, Boyett, J & Gajjar, A 2005, 'Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma', Journal of Clinical Oncology, vol. 23, no. 24, pp. 5511-5519. https://doi.org/10.1200/JCO.2005.00.703
Mulhern, Raymond K. ; Palmer, Shawna L. ; Merchant, Thomas E. ; Wallace, Dana ; Kocak, Mehmet ; Brouwers, Pim ; Krull, Kevin ; Chintagumpala, Murali ; Stargatt, Robyn ; Ashley, David M. ; Tyc, Vida L. ; Kun, Larry ; Boyett, James ; Gajjar, Amar. / Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 24. pp. 5511-5519.
@article{5240a9ad5c5544babda9ce547b83f3e6,
title = "Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma",
abstract = "Purpose: This prospective, longitudinal study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions of dose with age and time from diagnosis on intelligence quotient (IQ) and academic achievement (reading, spelling, and math) among patients treated for medulloblastoma (MB). Patients and Methods: Patients received serial neurocognitive testing spanning from 0 to 6.03 years after diagnosis (median, 3.14 years). The multi-institutional study included 111 patients, who were 3 to 20 years of age at diagnosis (median age, 7.4 years), treated for MB with risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and vincristine) with stem-cell support. High-risk patients (HR; n = 37) received CSI to 36 to 39.6 Gy and conformal boost treatment of the primary site to 55.8 to 59.4 Gy. Average-risk patients (AR; n = 74) received CSI to 23.4 Gy and conformal boost treatment of the posterior fossa to 36.0 Gy and primary site to 55.8 Gy. Results: Multivariate modeling revealed statistically significant declines in mean IQ (-1.59 points/yr; P= .006), reading (-2.95 points/yr; P < .0001), spelling (-2.94 points/yr; P < .0001), and math (-1.87 points/yr; P = .003) scores for the entire group. The effects of risk-adapted radiation therapy on IQ, reading, and spelling were moderated by age, with the greatest rates of decline observed for the HR patients who were younger (< 7 years old) at diagnosis. Conclusion: Young age at diagnosis was the most prominent risk factor for neurocognitive deficits among survivors of MB despite reductions in CSI dosing and efforts to limit the boost volume. Younger patients exhibited substantial problems with the development of reading skills.",
author = "Mulhern, {Raymond K.} and Palmer, {Shawna L.} and Merchant, {Thomas E.} and Dana Wallace and Mehmet Kocak and Pim Brouwers and Kevin Krull and Murali Chintagumpala and Robyn Stargatt and Ashley, {David M.} and Tyc, {Vida L.} and Larry Kun and James Boyett and Amar Gajjar",
year = "2005",
month = "12",
day = "1",
doi = "10.1200/JCO.2005.00.703",
language = "English (US)",
volume = "23",
pages = "5511--5519",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma

AU - Mulhern, Raymond K.

AU - Palmer, Shawna L.

AU - Merchant, Thomas E.

AU - Wallace, Dana

AU - Kocak, Mehmet

AU - Brouwers, Pim

AU - Krull, Kevin

AU - Chintagumpala, Murali

AU - Stargatt, Robyn

AU - Ashley, David M.

AU - Tyc, Vida L.

AU - Kun, Larry

AU - Boyett, James

AU - Gajjar, Amar

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Purpose: This prospective, longitudinal study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions of dose with age and time from diagnosis on intelligence quotient (IQ) and academic achievement (reading, spelling, and math) among patients treated for medulloblastoma (MB). Patients and Methods: Patients received serial neurocognitive testing spanning from 0 to 6.03 years after diagnosis (median, 3.14 years). The multi-institutional study included 111 patients, who were 3 to 20 years of age at diagnosis (median age, 7.4 years), treated for MB with risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and vincristine) with stem-cell support. High-risk patients (HR; n = 37) received CSI to 36 to 39.6 Gy and conformal boost treatment of the primary site to 55.8 to 59.4 Gy. Average-risk patients (AR; n = 74) received CSI to 23.4 Gy and conformal boost treatment of the posterior fossa to 36.0 Gy and primary site to 55.8 Gy. Results: Multivariate modeling revealed statistically significant declines in mean IQ (-1.59 points/yr; P= .006), reading (-2.95 points/yr; P < .0001), spelling (-2.94 points/yr; P < .0001), and math (-1.87 points/yr; P = .003) scores for the entire group. The effects of risk-adapted radiation therapy on IQ, reading, and spelling were moderated by age, with the greatest rates of decline observed for the HR patients who were younger (< 7 years old) at diagnosis. Conclusion: Young age at diagnosis was the most prominent risk factor for neurocognitive deficits among survivors of MB despite reductions in CSI dosing and efforts to limit the boost volume. Younger patients exhibited substantial problems with the development of reading skills.

AB - Purpose: This prospective, longitudinal study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions of dose with age and time from diagnosis on intelligence quotient (IQ) and academic achievement (reading, spelling, and math) among patients treated for medulloblastoma (MB). Patients and Methods: Patients received serial neurocognitive testing spanning from 0 to 6.03 years after diagnosis (median, 3.14 years). The multi-institutional study included 111 patients, who were 3 to 20 years of age at diagnosis (median age, 7.4 years), treated for MB with risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and vincristine) with stem-cell support. High-risk patients (HR; n = 37) received CSI to 36 to 39.6 Gy and conformal boost treatment of the primary site to 55.8 to 59.4 Gy. Average-risk patients (AR; n = 74) received CSI to 23.4 Gy and conformal boost treatment of the posterior fossa to 36.0 Gy and primary site to 55.8 Gy. Results: Multivariate modeling revealed statistically significant declines in mean IQ (-1.59 points/yr; P= .006), reading (-2.95 points/yr; P < .0001), spelling (-2.94 points/yr; P < .0001), and math (-1.87 points/yr; P = .003) scores for the entire group. The effects of risk-adapted radiation therapy on IQ, reading, and spelling were moderated by age, with the greatest rates of decline observed for the HR patients who were younger (< 7 years old) at diagnosis. Conclusion: Young age at diagnosis was the most prominent risk factor for neurocognitive deficits among survivors of MB despite reductions in CSI dosing and efforts to limit the boost volume. Younger patients exhibited substantial problems with the development of reading skills.

UR - http://www.scopus.com/inward/record.url?scp=24944564334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24944564334&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.00.703

DO - 10.1200/JCO.2005.00.703

M3 - Article

VL - 23

SP - 5511

EP - 5519

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -